Skip to content

Effect of vancomycin plus rifampicin in the treatment on methicillin-resistant Staphylococcus aureus pneumonia

Effect of vancomycin plus rifampicin in the treatment on methicillin-resistant Staphylococcus aureus pneumonia (Randomized prospective multicenter open-labelled study)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0000029
Enrollment
266
Registered
2010-09-02
Start date
2010-08-30
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients assigned to VR will receive vancomycin 1 g iv plus RFP 300 mg po every 12 h, and patients assigned to V receive vancomycin 1 g iv every 12 h.

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult patients = 18 years of age will be screened daily for clinical signs and symptoms consistent with nosocomial pneumonia, i.e., one developed 48 h or later after admission.: had to meet two criteria (a,b) a. A patient had to have a chest radiograph consistent with the diagnosis of pneumonia (new or persistent radiographic infiltrates(new or progressive infiltrates, consolidation, with/without pleural effusion b. Modified CPIS (clinical pulmonary infection score) = 4

Exclusion criteria

Exclusion criteria: a.presence ofmeningitis, endocarditis, or osteomyelitis b.bone marrow tranplantation or organ transplantation c.vancomycin treatment for = 48 h for any reason in the preceding week; d.elevated liver enzymes (= 3 times the upper limits of normal) or total bilirubin = 3.0 mg/dL e.severe neutropenia (< 1000 cells /mm3) or human immunodeficiency virus infection f.chemotherapy or persistent immunosuppression is needed g.a pathogen resistant to RFP or vancomycin

Design outcomes

Primary

MeasureTime frame
Clinical cure rate

Secondary

MeasureTime frame
microbiologic eradication;Mortality rate

Countries

Korea, Republic of

Contacts

Public ContactYoung Ju Jung

Asan Medical Center

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026